RT Journal Article
SR Electronic
A1 Boltz, Kathy
T1 Targeted and Salvage Therapies Benefit Patients With Thyroid Cancer
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 4
SP 25
OP 26
DO 10.1177/1559897715581829
UL http://mdc.sagepub.com/content/15/4/25.abstract
AB Sorafenib and lenvatinib can be effective for advanced differentiated thyroid cancer, and vandetanib and cabozantinib can be effective options for advanced medullary thyroid cancer. When first-line tyrosine kinase inhibitors fail for patients, evidence supports salvage therapy for differentiated thyroid cancer but is less compelling for medullary thyroid cancer.